ALICAPASE

COMPOSITION
Capivasertib……………………………………….200mg

INDICATIONS
• Capivasertib is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

PACKAGING: 64 Tablets/box.
Reg No: 07 L 1133/24
Download ALICAPASE Drug Registration Certificate


Brand name: Sotokras


Composition:
Each tablet contains:
Capivasertib……………………………………….200mg


Indication:
Capivasertib is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.


Dosage:
• Oral, 400mg each time, twice a day, for 4 days followed by 3 days off. Can be taken with or without food.


Contraindications: Allergic to any component of this product.


Warning:
• Regularly monitor blood sugar during treatment, and if there is an increase in blood sugar, reduce or discontinue medication according to the situation.
• Monitor the signs and symptoms of diarrhea in patients. It is recommended that patients increase their oral rehydration and begin antidiarrheal treatment when there are signs of diarrhea after taking this product.
• Serious skin adverse reactions may occur during the use of this medication.
• Female patients should take effective contraceptive measures during the medication period and within one month of the last administration, while male patients should take effective contraceptive measures during the medication period and within four months of the last administration.
• Pregnant and lactating women should use it with caution.
• Attention should be paid to the contraindications of fulvestrant when combined with fulvestrant.


Adverse effects:
• Diarrhea, skin adverse reactions, random elevated blood glucose, decreased lymphocytes, decreased hemoglobin, elevated fasting blood glucose, nausea and fatigue, leukopenia, increased triglycerides, neutropenia, elevated creatinine, vomiting, stomatitis.


Dosage form: White tablets.


Expiry date24 months after date of manufacture.


Packaging: 64 tablets per bottle.


Storage:
• Protected from light, sealed, and stored at 20℃- 25℃.
• Keep out of reach of children.


DISCLAIMER

The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.

For your safety:

Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.